Elivaldogene autotemcel - Biologic Drug Details

Summary for elivaldogene autotemcel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for elivaldogene autotemcel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for elivaldogene autotemcel Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bluebird Bio Inc.	SKYSONA	elivaldogene autotemcel	Injection	125755	10,563,172	2037-03-14	DrugPatentWatch analysis and company disclosures
Bluebird Bio Inc.	SKYSONA	elivaldogene autotemcel	Injection	125755	10,995,346	2037-07-14	DrugPatentWatch analysis and company disclosures
Bluebird Bio Inc.	SKYSONA	elivaldogene autotemcel	Injection	125755	11,274,301	2037-10-06	DrugPatentWatch analysis and company disclosures
Bluebird Bio Inc.	SKYSONA	elivaldogene autotemcel	Injection	125755	11,326,168	2039-11-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for elivaldogene autotemcel Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for elivaldogene autotemcel

Country	Patent Number	Estimated Expiration
Japan	4210116
European Patent Office	1214945
Japan	2010057515
World Intellectual Property Organization (WIPO)	03033700

Elivaldogene autotemcel Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Elivaldogene Autotemcel?

Elivaldogene autotemcel (Lenti-D), developed by Bluebird Bio, is a gene therapy approved for cerebral adrenoleukodystrophy (CALD). It targets a rare, life-threatening genetic disorder affecting myelin in the brain, primarily in boys aged 4 and above. Market factors hinge on disease prevalence, regulatory landscape, clinical efficacy, manufacturing capacity, and payer access.

Prevalence and Patient Pool

• CALD affects approximately 1 in 17,000 males aged 4 to 7 in the U.S.
• Estimated total U.S. patient population exceeds 300 qualified candidates annually.
• The global market remains limited due to low prevalence but high unmet need.

Competitive Landscape

• Only a handful of approved therapies for CALD, with Hematopoietic Stem Cell Transplant (HSCT) as the traditional standard.
• Elivaldogene autotemcel offers a potential for curative intervention, replacing HSCT’s limitations (donor availability, graft-versus-host disease).

Regulatory and Reimbursement Environment

• FDA approved in June 2022.
• Payer coverage varies; high treatment costs—around $3 million per dose—pose reimbursement challenges.
• Variability in hospital adoption and treatment centers influences market penetration.

Manufacturing and Supply Chain Considerations

• Autologous gene therapy production involves complex, costly processes.
• Capacity constraints limit supply, affecting accessibility.
• Distribution relies on specialized centers, limiting geographic reach.

Market Penetration and Adoption

• Early adoption is restricted to specialized centers.
• Patient and caregiver acceptance depends on perceived risk-benefit profile.
• Expansion into broader markets hinges on further clinical data, reimbursement, and infrastructure.

What Is the Financial Trajectory for Elivaldogene Autotemcel?

Bluebird Bio projects initial revenues from limited patient access, with growth driven by expanded diagnoses, increased treatment centers, and potential extension to other indications.

Revenue Projections

• First-year sales anticipated between $50 million and $100 million, based on initial treatment volumes.
• Growth rate targets range from 20% to 35% annually with increased adoption.
• Long-term revenue depends on market expansion and possible approval for other genetic indications.

Cost Structure and Margins

• High R&D and manufacturing costs produce gross margins approximately 60%-75% once scaled.
• Cost per patient exceeds $3 million, considering manufacturing, logistics, and clinical administration.
• Reimbursement negotiations and pricing strategies influence net margins.

Key Financial Milestones

• Market adoption within specialized centers by 2024-2025.
• Scaling manufacturing capacity anticipated by 2026 to meet demand.
• Potential pipeline additions (e.g., treatment for X-linked adrenoleukodystrophy) could diversify revenue.

Investment Outlook and Risks

• Limited patient pool constrains revenue potential.
• Pricing pressure and reimbursement challenges threaten revenue growth.
• Manufacturing bottlenecks and supply chain disruptions impact supply availability.
• Regulatory or safety concerns could hinder expansion.

What Are the Primary Opportunities and Risks?

Opportunities

• Increased diagnosis and awareness as genetic testing becomes routine.
• Potential expansion into additional orphan indications.
• Technological advances reducing manufacturing costs and batch variability.
• Policy shifts favoring high-cost therapies for rare diseases.

Risks

• Small patient base limits total market size.
• Significant upfront R&D and manufacturing expenses.
• Reimbursement uncertainties may cap revenue.
• Long-term safety data required to sustain market confidence.

Key Takeaways

• Elivaldogene autotemcel addresses an unmet need in a rare neurodegenerative disorder with high treatment costs.
• Market outlook depends on expanding treatment capacity, improving reimbursement access, and demonstrating long-term efficacy.
• Revenue projections are modest initially, with growth driven by superior clinical outcomes and expanded indications.
• Supply chain and manufacturing scalability remain critical hurdles.
• Competitive pressure hinges on the development of alternative therapies or improved treatments.

FAQs

1. What is the current regulatory status of elivaldogene autotemcel?
   Approved by the FDA in June 2022 for cerebral adrenoleukodystrophy.

2. What is the estimated patient population for this therapy?
   Approximately 300-400 eligible patients annually in the U.S., with global numbers proportionally lower.

3. How much does a treatment cycle cost?
   About $3 million per dose, covering manufacturing, logistics, and clinical administration.

4. What are the main barriers to market expansion?
   Limited treatment centers, high costs, reimbursement hurdles, and manufacturing capacity constraints.

5. Are there prospects for additional indications?
   Yes, research for other genetic neurodegenerative diseases may expand the approved use in the future.

---

References

[1] Bluebird Bio. “Elivaldogene autotemcel (Lenti-D) for CALD.” Regulatory filings, 2022.
[2] FDA. “Product Approval Announcement for Elivaldogene Autotemcel,” 2022.
[3] EvaluatePharma. “Gene Therapy Market Analysis,” 2023.
[4] IQVIA. “Orphan Drug Market Data,” 2023.
[5] Agency for Toxic Substances and Diseases Registry (ATSDR). “CALD Epidemiology,” 2022.